Dr Hamilton on HRQOL Differences With Gilteritinib vs Placeb

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Related Keywords

Betty Hamilton , Marrow Transplant Clinical Trials Network , Department Of Hematology , Medical Oncology , Cleveland Clinic , Functional Assessment , Cancer Therapy , Bone Marrow Transplant , Transplantation And Cellular Therapy Meetings , Onclive Tv , Hematologic Malignancies ,